Diclac 75 Duo

LEAFLET INCLUDED IN THE PACKAGING: INFORMATION FOR THE USER

Warning! Keep the leaflet, the information on the immediate packaging is in a foreign language!

Diclac 75 Duo(Diclo 75 SL - 1 A Pharma)

75 mg, prolonged-release tablets

Diclofenac sodium
Diclac 75 Duo and Diclo 75 SL - 1 A Pharma are different trade names for the same medicine.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed to you specifically. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Diclac 75 Duo and what is it used for
• 2. Important information before taking Diclac 75 Duo
• 3. How to take Diclac 75 Duo
• 4. Possible side effects
• 5. How to store Diclac 75 Duo
• 6. Contents of the pack and other information

1. What is Diclac 75 Duo and what is it used for

Diclac 75 Duo contains diclofenac sodium, which belongs to a group of so-called non-steroidal anti-inflammatory drugs (NSAIDs), which have anti-rheumatic, anti-inflammatory, analgesic, and antipyretic effects. The mechanism of action of Diclac 75 Duo involves the inhibition of prostaglandin biosynthesis, which plays a fundamental role in the pathogenesis of inflammation, pain, and fever.
Diclac 75 Duo is used to treat:

• inflammatory or degenerative forms of rheumatic disease: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spinal arthritis, pain syndromes associated with spinal changes, extra-articular rheumatism;
• pains caused by post-traumatic and post-operative inflammatory conditions and edema, e.g. after dental or orthopedic procedures;
• painful and/or inflammatory conditions in gynecology, e.g. primary dysmenorrhea or adnexitis.

Control tests during treatment with Diclac 75 Duo

In patients with diagnosed heart disease or significant risk factors for cardiovascular disease, the treating physician will periodically assess the patient's need for symptomatic treatment and their response to the medicine, especially if treatment lasts longer than 4 weeks.
During treatment, the physician will order regular blood tests to monitor liver function (aminotransferase activity), kidney function (creatinine levels), and blood cell count (white and red blood cells and platelets). Based on the test results, the physician will decide whether to discontinue treatment with Diclac 75 Duo or change the dose of the medicine.

2. Important information before taking Diclac 75 Duo

When not to take Diclac 75 Duo

• if the patient is allergic to diclofenac or any of the other ingredients of this medicine (listed in section 6),
• if the patient has ever had an allergic reaction after taking anti-inflammatory or analgesic medicines (e.g. acetylsalicylic acid, diclofenac, or ibuprofen). Reactions may include asthma, rhinitis, skin rash, urticaria, facial swelling, lip swelling, tongue swelling, throat swelling, and/or limb swelling (symptoms of angioedema). If the patient thinks they may be allergic, they should consult a doctor.
• if the patient has active or past stomach or duodenal ulcers, bleeding, or perforation; if the patient has ever experienced discomfort in the stomach area or heartburn after taking anti-inflammatory medicines,
• if the patient is in the last trimester of pregnancy,
• if the patient has liver failure,
• if the patient has kidney failure,
• if the patient has heart disease and/or cerebrovascular disease, e.g. after a heart attack, stroke, transient ischemic attack (TIA), or vascular occlusion, or after a procedure to clear or bypass blocked vessels,
• if the patient has circulation disorders (peripheral vascular disease).

The patient should inform their doctor about the presence of these diseases.

Warnings and precautions

Before taking Diclac 75 Duo, the patient should discuss it with their doctor if:

• the patient has diagnosed cardiovascular disease (see above) or significant risk factors, such as high blood pressure, elevated levels of fats in the blood (cholesterol, triglycerides), or if the patient is a smoker, as in such cases the dose of the medicine should not be increased above 100 mg per day if treatment lasts longer than 4 weeks;
• the patient has had a stomach ulcer or is elderly. Taking diclofenac may cause gastrointestinal bleeding, ulcers, or perforation (which may be life-threatening). This effect may be particularly dangerous in the case of high doses of the medicine. If any unusual abdominal symptoms occur during treatment with Diclac 75 Duo (especially gastrointestinal bleeding), the medicine should be discontinued immediately and the doctor consulted;
• the patient has ulcerative colitis or Crohn's disease, as diclofenac may exacerbate the disease;
• the patient has asthma, allergic rhinitis, nasal polyps, chronic obstructive pulmonary disease (COPD), or chronic respiratory infections, as they are more likely to experience an allergic reaction to diclofenac (exacerbation of asthma symptoms, angioedema, or urticaria). This warning also applies to patients allergic to other substances (e.g. those who experience skin reactions, itching, or urticaria). The medicine should be taken with caution (preferably under medical supervision);
• the patient has liver function disorders, as diclofenac may worsen the course of the disease. The patient should strictly follow the doctor's recommendations regarding liver function tests;
• the patient has porphyria, as diclofenac may trigger a porphyria attack.

Before taking diclofenac, the patient should inform their doctor if:

• they smoke,
• they have diabetes,
• they have angina pectoris, thrombosis, high blood pressure, elevated cholesterol levels, or elevated triglyceride levels.

The patient should use the smallest effective dose of Diclac 75 Duo that relieves pain and/or inflammation and use it for the shortest possible time to minimize the risk of side effects.
If at any time during treatment with Diclac 75 Duo the patient experiences symptoms suggesting heart or vascular problems, such as chest pain, shortness of breath, weakness, or slurred speech, they should immediately contact their doctor or hospital emergency department.
Taking diclofenac may, in very rare cases (especially at the beginning of treatment), cause life-threatening skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome with widespread rash, high fever, and joint pain, and toxic epidermal necrolysis with skin and mucous membrane changes, high fever, and severe general condition). After the first signs of rash, mucous membrane changes, or other symptoms of an allergic reaction, the medicine should be discontinued and the doctor consulted.
The medicine may mask the symptoms of infection (e.g. headache, elevated body temperature) and make it difficult to diagnose. During medical examinations, the patient should inform their doctor about taking the medicine.
Diclac 75 Duo should not be taken at the same time as other systemic non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors.
Before taking the medicine, the patient should inform their doctor or pharmacist about the presence of the above-mentioned diseases.
Taking such medicines as Diclac 75 Duo may be associated with a small increased risk of heart attack or stroke. This risk increases with long-term use of high doses of the medicine.
The patient should not take higher doses or use the medicine for longer than recommended.
In the event of heart problems, a history of stroke, or suspected risk of these disorders (e.g. high blood pressure, diabetes, elevated cholesterol levels, smoking), the patient should discuss their treatment with their doctor or pharmacist.
The medicine may temporarily inhibit platelet aggregation.

Children and adolescents

The medicine should not be used in children and adolescents due to the dose size.

Elderly patients (65 years and older)

Elderly patients may react more strongly to the medicine than other adults. The patient should follow the recommendations in the leaflet, take the medicine as directed by their doctor, use the smallest effective dose, and report all side effects that occur during treatment to their doctor.

Diclac 75 Duo and other medicines

The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.

The patient should especially inform their doctor about taking the following medicines:

• lithium or antidepressant medicines (selective serotonin reuptake inhibitors)
• digoxin - a medicine used to treat heart diseases
• diuretics - medicines that increase the amount of urine excreted
• angiotensin-converting enzyme (ACE) inhibitors, beta-blockers - a group of medicines used to treat high blood pressure and heart failure
• non-steroidal anti-inflammatory drugs (e.g. acetylsalicylic acid or ibuprofen) and corticosteroids (a group of medicines used to alleviate inflammatory conditions)
• anticoagulant and antiplatelet medicines
• antidiabetic medicines (except insulin)
• methotrexate - a medicine used to treat certain cancers or arthritis
• cyclosporine and tacrolimus - medicines used in organ transplant patients
• trimethoprim - a medicine used to prevent and treat urinary tract infections
• quinolone antibacterials - medicines used to treat infections
• cholestyramine and colestipol - medicines that lower cholesterol levels in the blood
• voriconazole - a medicine used to treat fungal infections
• phenytoin - a medicine used to treat epileptic seizures

Taking Diclac 75 Duo with food and drink

The tablets should be swallowed whole, with a glass of water, preferably during a meal.

Pregnancy, breastfeeding, and fertility

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine.
Pregnancy
Diclac 75 Duo should not be taken if the patient is in the last 3 months of pregnancy, as it may harm the unborn child or cause complications during delivery. Diclac 75 Duo may cause kidney and heart problems in the unborn child. It may also increase the risk of bleeding in the patient and the child and cause delayed or prolonged labor. During the first 6 months of pregnancy, Diclac 75 Duo should not be used unless the doctor considers it absolutely necessary. If treatment is necessary during this period or when trying to conceive, the smallest possible dose should be used for the shortest possible time. From the 20th week of pregnancy, Diclac 75 Duo may cause kidney problems in the unborn child if taken for more than a few days. This may lead to a low level of amniotic fluid surrounding the child (oligohydramnios) or narrowing of the blood vessel (ductus arteriosus) in the child's heart. If treatment is required for a longer period, the doctor may recommend additional monitoring.
Breastfeeding
Diclac 75 Duo should not be used in breastfeeding women, as it may harm the baby.
The doctor will discuss the potential risks of taking Diclac 75 Duo during pregnancy and breastfeeding with the patient.
Fertility
Taking Diclac 75 Duo may make it difficult to conceive. If the patient plans to conceive or has problems conceiving, they should inform their doctor.

Driving and using machines

The effect of Diclac 75 Duo on the ability to drive and use machines is unlikely.

Diclac 75 Duo contains lactose and sodium

If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".

3. How to take Diclac 75 Duo

This medicine should always be taken as directed by the doctor. If in doubt, the patient should consult their doctor or pharmacist.
The patient should not exceed the recommended dose. If Diclac 75 Duo is taken for more than a few weeks, the patient should have regular medical check-ups to rule out any unnoticed side effects.
The dose of the medicine is determined by the doctor individually for each patient. The rule is to use the smallest effective dose for the shortest possible time.
If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor.
Adults
1 tablet of Diclac 75 Duo (75 mg of diclofenac sodium) once a day. If necessary, the doctor may increase the dose to 2 tablets of Diclac 75 Duo (150 mg per day). The patient should not take a daily dose greater than 150 mg.
Use in children and adolescents
Due to the dose size, Diclac 75 Duo should not be used in children and adolescents under 18 years of age.
Elderly patients (65 years and older)
The medicine should be used with caution in elderly patients. In elderly patients and patients with low body weight, the smallest effective dose is recommended.
Diagnosed cardiovascular disease or significant cardiovascular risk factors
Patients with diagnosed cardiovascular disease or significant risk factors for cardiovascular events should take diclofenac only after their doctor has assessed their situation and only at a dose of ≤100 mg per day if treatment lasts longer than 4 weeks.
Kidney function disorders
Using Diclac 75 Duo in patients with kidney failure is contraindicated. No special studies have been conducted in patients with kidney function disorders, so no specific dosage recommendations can be made. In patients with mild to moderate kidney function disorders, caution is recommended.
Liver function disorders
Using Diclac 75 Duo in patients with liver failure is contraindicated. No special studies have been conducted in patients with liver function disorders, so no specific dosage recommendations can be made. In patients with mild to moderate liver function disorders, caution is recommended.

Method of administration

If the symptoms are most pronounced at night or in the morning, Diclac 75 Duo should be taken in the evening. The tablets should be swallowed whole, with a glass of water, preferably during a meal. The tablets should not be divided or chewed.

How long to take Diclac 75 Duo

Diclac 75 Duo should always be taken as directed by the doctor.
If the patient is taking Diclac 75 Duo for a long time, they should regularly consult their doctor to ensure that no side effects have occurred.
If in doubt about how long to take the medicine, the patient should consult their doctor or pharmacist.

Taking a higher dose of Diclac 75 Duo than recommended

Overdosing on Diclac 75 Duo does not cause characteristic symptoms, but the following may occur: vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus, or seizures. In the case of significant poisoning, acute kidney failure and liver damage may occur.
If the patient has accidentally taken more tablets than recommended, they should immediately consult their doctor, pharmacist, or go to the hospital emergency department.

Missing a dose of Diclac 75 Duo

If the patient misses a dose, they should take it as soon as they remember. However, if more than half of the time between two doses has passed, the patient should not take the missed dose but take the next tablet according to the previous dosing schedule. The patient should not take a double dose to make up for the missed dose.

4. Possible side effects

Like all medicines, Diclac 75 Duo can cause side effects, although not everybody gets them.
The following side effects are described below, which apply to diclofenac in the form of prolonged-release tablets and diclofenac in other pharmaceutical forms, used for short or long periods.

Side effects

Common(may occur in less than 1 in 10 people taking the medicine):

• headache, dizziness,
• nausea, vomiting, diarrhea, indigestion, abdominal pain, bloating, decreased appetite,
• increased aminotransferase activity,
• rash.

Uncommon(may occur in less than 1 in 100 people taking the medicine)

• myocardial infarction, heart failure, palpitations, chest pain.

Rare(may occur in less than 1 in 1000 people taking the medicine):

• hypersensitivity, anaphylactic and pseudoanaphylactic reactions (including sudden drop in blood pressure and shock),
• drowsiness,
• asthma (including shortness of breath),
• gastritis, gastrointestinal bleeding, bloody vomiting, bloody diarrhea, melena,
• peptic ulcer disease (with or without bleeding and perforation),
• hepatitis, jaundice, liver function disorders,
• urticaria,
• edema.

Very rare(may occur in less than 1 in 10,000 people taking the medicine):

• thrombocytopenia (decreased platelet count), leukopenia (decreased white blood cell count), anemia (including hemolytic and aplastic anemia), agranulocytosis (decreased or absent granulocytes),
• angioedema (including facial swelling),
• disorientation, depression, insomnia, nightmares, irritability, psychotic disorders,
• paresthesia, memory disorders, seizures, anxiety, tremors, aseptic meningitis, taste disorders, cerebrovascular accident,
• vision disorders, blurred vision, double vision,
• tinnitus, hearing disorders,
• hypertension, vasculitis,
• pneumonitis,
• ulcerative colitis (including bloody colitis and exacerbation of ulcerative colitis and Crohn's disease), constipation, oral mucositis (including ulcerative stomatitis), glossitis, esophageal disorders, intestinal stricture, pancreatitis,
• fulminant hepatitis, liver necrosis, liver failure,
• bullous rash, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), exfoliative dermatitis, alopecia, photosensitivity reactions, purpura, Henoch-Schönlein purpura, pruritus.

Frequency not known(frequency cannot be estimated from the available data)

• concomitant occurrence of chest pain and allergic reaction (symptoms of Kounis syndrome).

Taking such medicines as Diclac 75 Duo may be associated with a small increased risk of heart attack or stroke.
Some patients taking Diclac 75 Duo may experience other side effects, not listed in this leaflet. If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist.

If any of the following side effects occur, the patient should stop taking Diclac 75 Duo and inform their doctor:

• discomfort in the stomach, heartburn, or abdominal pain
• bloody vomiting, blood in stool, blood in urine
• skin disorders such as rash or itching
• shortness of breath or difficulty breathing
• yellowing of the skin or whites of the eyes
• prolonged sore throat or high fever
• swelling of the face, feet, or legs
• severe migraine
• chest pain accompanied by coughing
• mild painful abdominal cramps and tenderness, starting soon after taking Diclac 75 Duo, followed by rectal bleeding or bloody diarrhea, usually within 24 hours of abdominal pain (frequency not known).

Some side effects can be serious

These uncommon side effects may occur in 1 to 10 patients per 1000, especially when taking high daily doses (150 mg) for a long time

• sudden, crushing chest pain (symptoms of myocardial infarction).
• shortness of breath, difficulty breathing when lying down, swelling of the feet or legs (symptoms of heart failure).

If the patient is taking Diclac 75 Duo for more than a few weeks, they should regularly consult their doctor to ensure that no side effects have occurred.

Reporting suspected side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Diclac 75 Duo

• The medicine should be stored out of sight and reach of children.
• There are no special storage recommendations.
• The medicine should not be used after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month stated.
• The batch number on the carton is marked as "Lot".
• Translation of some information on the immediate packaging: Ch.-B./verwendbar bis: see imprint - batch number/expiry date: see imprint.
• Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What Diclac 75 Duo contains

• The active substance of the medicine is diclofenac sodium. One prolonged-release tablet contains 75 mg of diclofenac sodium.
• The other ingredients are: lactose monohydrate, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, magnesium stearate, sodium carboxymethylcellulose (type A), anhydrous colloidal silica, corn starch, red iron oxide (E 172); hypromellose.

What Diclac 75 Duo looks like and contents of the pack

Diclac 75 Duo tablets consist of two layers: pink and white.
They are packaged in PP/Aluminum or PVC/PVDC/Aluminum blisters in a carton.
The packs contain 10 or 20 prolonged-release tablets.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Germany, the country of export:

1 A Pharma GmbH
Industriestraße 18
83607 Holzkirchen
Germany

Manufacturer:

Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben
Germany

Parallel importer:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź

Repackaged by:

Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
SHIRAZ PRODUCTIONS Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
Marketing authorization number in Germany, the country of export: 48728.00.00
Parallel import authorization number: 200/23

Date of leaflet approval: 18.09.2023

[Information about the trademark]